GUTLAB – A SMART PILL FOR REMOTE HEALTH MONITORING VIA THE GUT MICROBIOME

Enteromics正在通过开发一个平台，通过肠道微生物组实现远程健康监测，解决未解决的长寿挑战。肠道微生物群对健康至关重要——它会影响你的新陈代谢、免疫系统，甚至大脑功能。我们吃的食物、药物、运动、睡眠和压力都会影响肠道微生物群，并可能导致它被破坏，导致许多疾病，如肥胖、肠道问题，甚至阿尔茨海默氏症。Enteromics正在提供一种可食用的智能传感药丸，它可以跟踪微生物群，并实时向智能手机应用程序提供反馈。Enteromics是由材料科学家菲比·赫塞尔廷（Phoebe Heseltine）和生物技术专家玛丽亚姆·埃尔加布里（Mariam Elgabry）于2019年创立的初创公司。他们正在开发一系列智能药丸，以监测和检测慢性疾病，首先是炎症性肠病（IBD）。通过这项创新的英国智能补助金，通过联合创始人的初步研究开发的可食用设备的核心部件将与伦敦大学学院合作，对其安全性和性能进行评估。在这笔拨款中开展的工作对于发展强大的知识产权地位和确定下一步的制造步骤至关重要，这将使Enteromics能够将这项技术推向市场。运动、营养、睡眠和其他生活方式因素，以及提供的药物治疗，对肠道微生物群有直接影响，这为通过持续监测微生物群来更好地管理慢性疾病提供了机会。如果成功，该技术将优于现有的微生物取样方法，如粪便取样，这些方法不方便，昂贵且提供结果缓慢。该产品将首先在英国推出，服务于IBD患者。IBD是一种慢性复发性胃肠疾病，目前尚无治愈方法。英国的IBD患病率是世界上第二高的，每年花费NHS 7.2亿英镑。在英国成功推出后，该技术将在北美销售，北美是可摄取传感器和微生物组产品增长最快的市场。许多患者反复寻求治疗，频繁的侵入性医学检查，无效的治疗处方和手术。在IBD患者中，肠道微生物组变化与疾病发作之间存在非常密切的联系。有了Enteromics的技术，个人将能够以一种医学上安全、方便和有效的方式监测自己的状况。Enteromics看到他们的技术扩展到其他慢性疾病的管理以及消费者应用。

Enteromics are addressing the unmet challenge of longevity through developing a platform that enables remote health monitoring via the gut microbiome. The gut microbiome is crucial to health -- it affects your metabolism, immune system and even brain function. The food we eat, medications, exercise, sleep and stress all affect the gut microbiome and can cause it to become disrupted, leading to many diseases such as obesity, gut problems and even Alzheimer's. Enteromics is providing an ingestible smart sensing pill that tracks the microbiome and provides feedback to a smartphone App, in real-time.Enteromics is a start-up founded in 2019 by Phoebe Heseltine, a materials scientist and Mariam Elgabry, a biotechnologist. They are developing a range of smart pills to monitor and detect chronic diseases, beginning with Inflammatory Bowel Disease (IBD).Through this innovate UK Smart Grant, the core components of the ingestible device -- developed through the co-founders' initial research -- will be evaluated for safety and performance, in partnership with University College London. The work carried out in this grant is key to developing a strong IP position and determining the next steps to manufacturing, which will enable Enteromics to bring this technology to market.Exercise, nutrition, sleep and other lifestyle factors, as well as drug treatments offered, have an immediate effect on the gut microbiome and this provides a window of opportunity for better management of chronic conditions through continuous microbiome monitoring. If successful, the technology will outperform existing methods of sampling the microbiome such as faecal sampling, which are inconvenient, expensive and slow to provide results.The product will first launch in the UK to serve sufferers of IBD, a chronic relapsing gastrointestinal disorder for which there is no cure. IBD prevalence in the UK is second highest in the world, costing the NHS £720 million a year. Following successful launch in the UK the technology will be sold in North America, the fastest growing market for both ingestible sensors and microbiome products.Many sufferers seek repeated medical care for flare-ups, with frequent invasive medical exams, prescription of ineffective treatments and surgery. In IBD patients there is a very strong link between gut microbiome changes and disease flare-ups. With Enteromics' technology, individuals will be able to monitor their condition in a way that is medically safe, convenient and effective. Enteromics see their technology expanding into management of other chronic conditions as well as in consumer applications.